ATE429210T1 - Orale flüssige zusammensetzungen - Google Patents

Orale flüssige zusammensetzungen

Info

Publication number
ATE429210T1
ATE429210T1 AT99901487T AT99901487T ATE429210T1 AT E429210 T1 ATE429210 T1 AT E429210T1 AT 99901487 T AT99901487 T AT 99901487T AT 99901487 T AT99901487 T AT 99901487T AT E429210 T1 ATE429210 T1 AT E429210T1
Authority
AT
Austria
Prior art keywords
oral liquid
liquid compositions
pharmaceutical compositions
present
preparing
Prior art date
Application number
AT99901487T
Other languages
English (en)
Inventor
Edward Wilson
Laura Trespidi
Christy Clark
Ashok Desai
Glenn Meyer
Original Assignee
Applied Analytical Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Analytical Ind Inc filed Critical Applied Analytical Ind Inc
Application granted granted Critical
Publication of ATE429210T1 publication Critical patent/ATE429210T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
AT99901487T 1998-01-20 1999-01-15 Orale flüssige zusammensetzungen ATE429210T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7186598P 1998-01-20 1998-01-20
PCT/US1999/000925 WO1999036060A1 (en) 1998-01-20 1999-01-15 Oral liquid compositions

Publications (1)

Publication Number Publication Date
ATE429210T1 true ATE429210T1 (de) 2009-05-15

Family

ID=22104103

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99901487T ATE429210T1 (de) 1998-01-20 1999-01-15 Orale flüssige zusammensetzungen

Country Status (10)

Country Link
US (1) US6287594B1 (de)
EP (1) EP1049459B1 (de)
JP (1) JP2002509103A (de)
KR (1) KR100610403B1 (de)
AT (1) ATE429210T1 (de)
AU (1) AU2117399A (de)
CA (1) CA2318128C (de)
DE (1) DE69940769D1 (de)
NO (1) NO20003698L (de)
WO (1) WO1999036060A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6719999B2 (en) * 1999-03-31 2004-04-13 Abbott Laboratories Formulations comprising lipid-regulating agents
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US6437006B1 (en) 1999-09-27 2002-08-20 American Cyanamid Company Pharmaceutical carrier formulation
CN1399542A (zh) * 1999-09-27 2003-02-26 美国氰胺公司 药用载体制剂
US6352718B1 (en) 1999-09-27 2002-03-05 American Cyanamid Company Vasopressin antagonist formulation and process
CZ20021083A3 (cs) * 1999-09-27 2002-06-12 American Cyanamid Company Farmaceutický prostředek
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
CA2388240C (en) * 1999-11-05 2010-04-20 Emisphere Technologies, Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
WO2001037834A1 (en) * 1999-11-22 2001-05-31 Galephar Pharmaceutical Research, Inc. Stable acid labile benzimidazole pharmaceutical compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
JP4501054B2 (ja) * 2000-10-24 2010-07-14 味の素株式会社 ナテグリニド含有製剤
WO2002100394A1 (en) * 2001-06-12 2002-12-19 Galephar M/F Oral pharmaceutical composition containing a statin derivative
US7855082B1 (en) 2001-10-31 2010-12-21 Astrazeneca Ab Raman spectroscopic method for determining the ratio of 5-methoxy and 6-methoxy isomers of omeprazole
KR20030042935A (ko) * 2001-11-26 2003-06-02 알앤피코리아 주식회사 클로닉신리신 제제
WO2003045331A2 (en) 2001-11-29 2003-06-05 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
JP4452970B2 (ja) 2002-03-27 2010-04-21 日本臓器製薬株式会社 ジクロフェナクナトリウム経口製剤
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US20040006109A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of non-enterically coated acid-labile drugs
EP1545477A4 (de) * 2002-09-13 2006-11-22 Cydex Inc Kapseln mit wässrigen füllzusammensetzungen, stabilisiert mit derivatisiertem cyclodextrin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20050203115A1 (en) * 2004-03-10 2005-09-15 Sancilio Frederick D. Narcotic-NSAID ion pairs
WO2006052922A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
US20060105045A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
US20070053868A1 (en) 2005-03-08 2007-03-08 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
US20070003621A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Dosage forms for movement disorder treatment
CA2615941A1 (en) * 2005-08-05 2007-02-15 Orbus Pharma Inc. Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor
CA2627292C (en) 2005-10-26 2012-04-17 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
WO2007050724A2 (en) 2005-10-26 2007-05-03 Banner Pharmacaps, Inc. Lipophilic vehicle-based dual controlled release matrix system as capsule fill
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
GB0525461D0 (en) 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
US20090247603A1 (en) * 2005-12-23 2009-10-01 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
EP2522344A1 (de) 2006-03-28 2012-11-14 Javelin Pharmaceuticals, Inc. Formulierungen aus niedrigdosiertem Diclofenac und Beta-Cyclodextrin
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
US20100316712A1 (en) * 2006-12-22 2010-12-16 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
NZ579972A (en) * 2007-05-24 2012-03-30 Novartis Ag Oral dosage form of diclofenac providing fast absorption of drug
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
EP3354276B1 (de) 2007-11-13 2020-01-01 Meritage Pharma, Inc. Zusammensetzungen zur behandlung von magen-darm-entzündung
US7662858B2 (en) 2008-05-23 2010-02-16 Aaipharma, Inc. Method of treating post-surgical acute pain
DE102009028076A1 (de) * 2009-07-29 2011-02-03 Evonik Röhm Gmbh Beschichtungsmittel zum Tauchbeschichten von Kapselhälften
US9107451B2 (en) * 2009-07-29 2015-08-18 Evonik Röhm Gmbh Coating composition for the dip coating of capsule halves
CA2690490C (en) * 2010-01-19 2012-06-26 Accucaps Industries Limited Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
CA2690488C (en) * 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20160243044A1 (en) * 2015-02-20 2016-08-25 Enspire Group LLC Soft gelatin capsules containing fexofenadine
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
EP3544614A4 (de) 2016-11-28 2020-08-05 Lipocine Inc. Orale testosteron-undecanoat-therapie
JP6943384B2 (ja) * 2017-03-01 2021-09-29 ヱスビー食品株式会社 食品の食感劣化防止用ソフトカプセル、並びに、該食感劣化防止用ソフトカプセル及び食用油を含有する食品
WO2020018974A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4028772A (en) 1971-04-02 1973-09-27 Merck & Co., Inc Chemical processes
DE2861413D1 (en) * 1977-10-13 1982-01-28 Sanraku Ocean Co Thienamycin related antibiotics ps-6 and ps-7, process for their production and compositions containing them
HU185926B (en) 1979-09-27 1985-04-28 Agostne Kahan Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
HU207078B (en) * 1988-08-02 1993-03-01 Glaxo Group Ltd Process for producing lactam derivatives and pharmaceutical compositions comprising such compounds
US4880835A (en) 1988-11-03 1989-11-14 Formulations Development Labs, Inc. Oral liquid pharmaceutical compositions of sulindac
CA2017916C (en) * 1989-06-07 1999-02-02 Minoru Aoki Etoposide preparations
US5024997A (en) * 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
US5141961A (en) * 1991-06-27 1992-08-25 Richrdson-Vicks Inc. Process for solubilizing difficulty soluble pharmaceutical actives
US5183829A (en) 1991-09-27 1993-02-02 Applied Analytical Industries, Inc. Oral liquid compositions of non-steroidal anti-inflammatory drugs
US5505961A (en) * 1993-08-05 1996-04-09 R. P. Scherer Corporation Gelatin capsules containing a highly concentrated acetaminophen solution
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
SK96196A3 (en) * 1994-01-24 1997-03-05 Procter & Gamble Process for solubilizing difficultly soluble pharmaceutical actives
ES2088742B1 (es) * 1994-06-29 1997-03-16 Salvat Lab Sa Composicion antibiotica de aplicacion otica.
US5616621A (en) * 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
US5641512A (en) 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US5516789A (en) * 1995-04-12 1996-05-14 Abbott Laboratories Lipoxygenase and cyclooxygenase inhibiting compounds
US6013280A (en) 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres

Also Published As

Publication number Publication date
NO20003698D0 (no) 2000-07-19
AU2117399A (en) 1999-08-02
EP1049459A1 (de) 2000-11-08
EP1049459B1 (de) 2009-04-22
CA2318128C (en) 2008-10-14
US6287594B1 (en) 2001-09-11
KR100610403B1 (ko) 2006-08-10
EP1049459A4 (de) 2005-04-20
NO20003698L (no) 2000-09-12
JP2002509103A (ja) 2002-03-26
KR20010052149A (ko) 2001-06-25
WO1999036060A1 (en) 1999-07-22
DE69940769D1 (de) 2009-06-04
CA2318128A1 (en) 1999-07-22

Similar Documents

Publication Publication Date Title
DE69940769D1 (de) Orale flüssige zusammensetzungen
HRP20020045A2 (en) Oral liquid compositions
TR200101412T2 (tr) Yeni bileşikler.
ATE113604T1 (de) Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
NO20034230L (no) 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister
DE60108236D1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
EP1015008A4 (de) Verbindungen und zusammensetzungen zur administration aktiver stoffe
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
IS6658A (is) Ný efnasambönd
DE69940674D1 (de) Orale verabreichung von adenosin analogen
KR890700125A (ko) 신규 벤즈이미다졸 유도체, 그 제조방법 및 이 화합물을 함유하는 제약 조성물
EE05091B1 (et) Oligosahhariidid, nende valmistamismeetod ja kasutamine ning farmatseutilised kompositsioonid
UA66861C2 (uk) 2-феніл-1-[4-(2-аміноетокси)бензил]індол в комбінації з естрогенами, способи лікування та продукт для лікування
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
ATE215817T1 (de) Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis
DE69422712D1 (de) Tris-platin-komplexe
ES2132556T3 (es) Nuevo derivado de benzo-tiadiazina, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen.
NO20020914D0 (no) Alkoksy-substituerte benzimidazolforbindelser, preparater inneholdende slike samt anvendelser derav
DE60032372D1 (de) Arzneizubereitungen enthaltend paclitaxel eingeschlossen in nanopartikeln von polymerischen mizellen
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
DK1061938T3 (da) Orale sammensætninger med cytotoksiske proteiner i lav dosis
ATE402178T1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza- benzoäcüfluoren-6-carbonsäurederivate als nmda- antagonisten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties